ArticlePharmaceuticals (Basel, Switzerland)2026
Adalimumab Safety in Inflammatory Bowel Disease: A Clinical Cohort Study with Time-to-Event Analysis and FAERS Signal Assessment.
Bojana Milašinović et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.